Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Bordoni R, Ciardiello F, von Pawel J, et al. Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19:441–9 e4.
   PubMed Web of Science ®Google Scholar
• Bi N, Liu L, Liang J, et al. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. BMC Cancer. 2020;20:278.
   PubMed Web of Science ®Google Scholar
• Wu J, Qi X, Liu L, et al. Emerging epigenetic regulation of circular RNAs in human cancer. Mol Ther Nucleic Acids. 2019;16:589–596.
   PubMedGoogle Scholar
• Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. Expert Rev Respir Med. 2020;14:125–136.
   PubMed Web of Science ®Google Scholar
• Adrianzen Herrera D, Ashai N, Perez-Soler R, et al. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert Opin Pharmacother. 2019;20:95–102.
   PubMed Web of Science ®Google Scholar
• Shen W, Pang H, Liu J, et al. Epithelial-mesenchymal transition contributes to docetaxel resistance in human non-small cell lung cancer. Oncol Res. 2014;22:47–55.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lin H, Gan Y, et al. P16 methylation leads to paclitaxel resistance of advanced non-small cell lung cancer. J Cancer. 2019;10:1726–1733.
   PubMed Web of Science ®Google Scholar
• Wang N, Song L, Xu Y, et al. Loss of scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine. 2019;47:65–77.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–338.
   PubMed Web of Science ®Google Scholar
• Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32:453–461.
   PubMed Web of Science ®Google Scholar
• Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22:256–264.
   PubMed Web of Science ®Google Scholar
• Yang T, Chen Y, Zhao P, et al. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules. Nanomedicine. 2018;14:2009–2021.
   PubMed Web of Science ®Google Scholar
• Patop IL, Kadener S. circRNAs in cancer. Curr Opin Genet Dev. 2018;48:121–127.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng R, Chen J, et al. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell Int. 2020;20:289.
   PubMed Web of Science ®Google Scholar
• Sun H, Chen Y, Fang YY, et al. Circ_0000376 enhances the proliferation, metastasis, and chemoresistance of NSCLC cells via repressing miR-384. Cancer Biomark. 2020;29:463–473.
   PubMed Web of Science ®Google Scholar
• Li YH, Xu CL, He CJ, et al. circMTDH.4/miR-630/AEG-1 axis participates in the regulation of proliferation, migration, invasion, chemoresistance, and radioresistance of NSCLC. Mol Carcinog. 2020;59:141–153.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang H, Jiang H, et al. Circ_0011292 enhances paclitaxel resistance in non-small cell lung cancer by regulating miR-379-5p/TRIM65 axis. Cancer Biother Radiopharm. 2020. DOI:10.1089/cbr.2019.3546
   Web of Science ®Google Scholar
• Fu Y, Huang L, Tang H, et al. hsa_circRNA_012515 is highly expressed in NSCLC patients and affects its prognosis. Cancer Manag Res. 2020;12:1877–1886.
   PubMedGoogle Scholar
• Yao JT, Zhao SH, Liu QP, et al. Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value. Pathol Res Pract. 2017;213:453–456.
   PubMed Web of Science ®Google Scholar
• Yu C, Ying J, Yu K, et al. Circ_0074027 contributes to nonsmall cell lung cancer progression by upregulating CUL4B expression through miR-335-5p. Cancer Biother Radiopharm. 2020. DOI:10.1089/cbr.2020.3579
   Web of Science ®Google Scholar
• Gao P, Wang Z, Hu Z, et al. Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation. J Cell Biochem. 2020;121:2632–2642.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Yin J, Peng G, et al. Circ_0074027 contributes to the progression of non-small cell lung cancer via microRNA-362-3p/clathrin heavy chain axis. Anticancer Drugs. 2021;32:1–10.
   PubMed Web of Science ®Google Scholar
• Duan Z, Wei S, Liu Y. Circ_0074027 contributes to non-small cell lung cancer progression through positively modulating RHOA via sequestering miR-2467-3p. J Bioenerg Biomembr. 2021;53:223–233.
   PubMed Web of Science ®Google Scholar
• Aras M, Erdil TY, Dane F, et al. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun. 2016;37:9–15.
   PubMed Web of Science ®Google Scholar
• Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non-small-cell lung cancer. Clin Lung Cancer. 2020;21:e191–e204.
   PubMed Web of Science ®Google Scholar
• Sharma A. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017;12:2137–2148.
   PubMed Web of Science ®Google Scholar
• Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang M, Zhang Y. Circ_0000079 decoys the RNA-binding protein FXR1 to interrupt formation of the FXR1/PRCKI complex and decline their mediated cell invasion and drug resistance in NSCLC. Cell Transplant. 2020;29:963689720961070.
   PubMed Web of Science ®Google Scholar
• Ji W, Diao YL, Qiu YR, et al. LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. Cell Death Dis. 2020;11:16.
   PubMed Web of Science ®Google Scholar
• Liang M, Chen H, Min J. miR-379-5p inhibits proliferation and invasion of the endometrial cancer cells by inhibiting expression of ROR1. Acta Biochim Pol. 2021. DOI:10.18388/abp.2020_5538
   Web of Science ®Google Scholar
• Jun L, Xuhong L, Hui L. Circ_SIPA1L1 promotes osteosarcoma progression via miR-379-5p/MAP3K9 axis. Cancer Biother Radiopharm. 2020. DOI:10.1089/cbr.2020.3891
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhu P, Gao Y, et al. miR3795p inhibits cell proliferation and promotes cell apoptosis in nonsmall cell lung cancer by targeting betaarrestin1. Mol Med Rep. 2020;22:4499–4508.
   PubMed Web of Science ®Google Scholar
• Tang D, Gao W, Yang J, et al. miR181d promotes cell proliferation via the IGF1/PI3K/AKT axis in glioma. Mol Med Rep. 2020;22:3804–3812.
   PubMed Web of Science ®Google Scholar
• Yuan L, Zhou C, Lu Y, et al. IFN-gamma-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. Cancer Lett. 2015;359:136–147.
   PubMed Web of Science ®Google Scholar
• Tang H, Bai Y, Pan G, et al. Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC. Autoimmunity. 2018;51:399–407.
   PubMed Web of Science ®Google Scholar
• Tian F, Wang Y, Xiao Z, et al. [Circular RNA CircHIPK3 promotes NCI-H1299 and NCI-H2170 cell proliferation through miR-379 and its target IGF1]. Zhongguo Fei Ai Za Zhi. 2017;20:459–467.
   PubMedGoogle Scholar
• Wu X, Wu Q, Zhou X, et al. SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: a preliminary in vitro study. J Cancer. 2019;10:4264–4269.
   PubMed Web of Science ®Google Scholar